Advanced search
Publication Cover
Current Eye Research Volume 19, 1999 - Issue 3
Submit an article Journal homepage
13
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Doxorubicin does not spread systemically following a local injection into the eyelids of rabbits

Linda Kirschen McLoon Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota 55455
,
Kristopher Josephson Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota 55455
&
Jonathan Wirtschafter Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota 55455
Pages 285-289 | Published online: 02 Jul 2009

References

  • Wirtschafter JD. Clinical doxorubicin chemomyectomy: an experimental treatment for muscle spasms. Ophthal-mology. 1991;98:357–366.
  • Wirtschafter JD. Chemomyectomy of the orbicularis oculi muscles for the treatment of localized hemifacial spasm. J Neuro-ophthal. 1994;14:199–204.
  • McLoon LK, Bauer G, Wirtschafter JD. Quantification of muscle loss in the doxorubicin treated orbicularis oculi muscle of the monkey. Invest Ophthal Vis Sci. 1991;32: 1667–1673.
  • McLoon LK, Luo XX, Wirtschafter JD. Acute morpho-logic changes in orbicularis oculi muscle after doxoru-bicin injection into rabbit eyelid. Muscle Nerve. 1993; 16:737–743.
  • McLoon LK, Wirtschafter JD, Cameron JD. Muscle loss from doxorubicin injections into the eyelids of a patient with blepharospasm. Amer J Ophthal. 1993;116:646–648.
  • Arcamone F. Doxorubicin, Anticancer Antibiotics: Me-dicinal Chemistry, New York, Academic Press, 1991:Vol. 17.
  • Lefrak EA, Pitha J, Rosenheim S, Gottlieb A. A clinico-pathologic analysis of Adriamycin cardiotoxicity. Can-cer. 1973;32:302–314.
  • Lenaz L, Page J. Cardiotoxicity of Adriamycin and re-lated anthracyclines. Cancer Treat Rev. 1976;3:111–120.
  • Mazue G, Iatropoulos M, Imondi A, Castellino S, Brughera M, Podesta A, Della Torre P, Moneta D. Anthracyclines: a review of general and special toxic-ity studies. Int J Oncol. 1995;7:713–726.
  • Speth PAJ, van Hoesel QGCM, Haanen C. Clinical phar-macokinetics of doxorubicin. Clin Pharmacokin. 1988; 15:15–31.
  • Underferth DV, Magorien RD, Unverferth BP, Talley RL, Balzerzak SP, Baba N. Human myocardial morphologic and functional changes in the first 24 hours after doxo-rubicin administration. Cancer Treat Rep. 1981;65:1093–1097.
  • Rudolph R, Stein RS, Patillo RA. Skin ulcers due to Adriamycin. Cancer. 1976;38:1087–1094.
  • Bowers DG, Lynch JB. Adriamycin extravasation. Plast Recontr Surg. 1978;61:686–692.
  • Jones AP, Crawford SM. Anthracycline induced toxic-ity affecting palmar and plantar skin. Brit J Cancer. 1989;59:814.
  • McLoon LK, Wirtschafter JD. Doxorubicin chemo-myectomy: injection of monkey orbicularis oculi results in selective muscle injury. Invest Ophthal Vis Sci. 1988;29:1854–1859.
  • Rose LM, Tillery KF, El Dareer SM, Hill DL. High-per-formance liquid chromatographic determination of doxo-rubicin and its metabolites in plasma and tissue. J Chromat. 1988;425:419–423.
  • Lange DJ, Brin MF, Warner CL, Fahn S, Lovelace RE. Distant effects of local injection of botulinum toxin. Muscle & Nerve. 10,522–555.
  • Zuber M, Sebald M, Bathien N, de Recondo J, Rondot P. Botulinum antibodies in dystonic patients treated with type A botulinum toxin: frequency and significance. Neurology. 1993;43:1715–1718.
  • Don RT, Alberts DS, Chen HSG. Experimental model of doxorubicin extravasation in the mouse. J Pharmacol Meth. 1980;4:321–334.
  • Sonneveld P, Wassenaar HA, Nooter K. Long persistence of doxorubicin in human skin after extravasation. Can-cer Treatment Rep. 1984;68:895–896.
  • Wirtschafter JD, McLoon LK. Long-term efficacy of lo-cal doxorubicin chemomyectomy in blepharospasm and hemifacial spasm patients. Ophthalmology. 1998;105: 342–346.
  • McLoon LK, Kirsch J, Cameron S, Wirtschafter JD. In-jection of doxorubicin into rabbit eyelid does not re-sult in loss of facial motor neurons. Brain Res. 1994;641: 105–110.
  • Preiss R, Sohr R, Kittelmann B, Muller E, Haase D. In-vestigations on the dose-dependent pharmacokinetics of adriamycin and its metabolites. Int J Clin Pharmacol Therap Toxicol. 1989;27:156–164.
  • Jacquet JM, Bressolle F, Galtier M, Bourrier M, Donadio D, Joudan J, Rossi JF. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol. 1990;27:219–225.
  • Baurain R, Deprez-De Campeneere D, Trouet A. Determination of daunorubicin, doxorubicin and their fluorescent metabolites by high-pressure liquid chroma-tography: plasma levels in DBA, mice. Cancer Che-mother Pharmacol. 1979;2:11–14.
  • Cusack BJ, Young SP, Driskell J, Olson RD. Doxorubicin and doxorubicinol pharmacokinetics and tissue concen-trations following bolus injection and continuous in-fusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol. 1993;32:53–58.
  • Takanashi S, Bachur NR. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Disp. 1976;4:79–87.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.